Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLPG | US
0.82
2.89%
Healthcare
Biotechnology
30/06/2024
04/10/2024
29.19
28.27
29.19
28.27
Galapagos NV an integrated biopharmaceutical company engages in the discovery development and commercialization of"various medicines for high unmet medical need. Its pipeline products include filgotinib a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis Crohn's disease ulcerative colitis ankylosing spondylitis psoriatic arthritis and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201 CD19 CAR-T product candidate manufactures at point-of-care that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences Inc.; AbbVie S.Ã r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen Belgium."
View LessStrength based on increasing price with high volume
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.7%1 month
28.2%3 months
36.5%6 months
29.6%55.25
166.67
0.60
-
-
-31.50
1.18
-
-101.32M
1.92B
1.92B
-
-49.03
74.80
29.70
1.15
7.06
2.99
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.89
Range1M
3.53
Range3M
6.90
Rel. volume
1.25
Price X volume
4.40M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Centessa Pharmaceuticals plc American Depositary Shares | CNTA | Biotechnology | 15.94 | 2.05B | -1.97% | n/a | 29.85% |
Akero Therapeutics Inc | AKRO | Biotechnology | 28.24 | 2.04B | -3.32% | n/a | 4.54% |
Celldex Therapeutics Inc | CLDX | Biotechnology | 30.65 | 2.03B | 1.46% | n/a | 0.29% |
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 34.6 | 2.00B | -2.73% | 20.07 | 40.71% |
Maravai LifeSciences Holdings Inc | MRVI | Biotechnology | 7.89 | 1.99B | -0.13% | n/a | 128.60% |
Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 104.78 | 1.95B | 4.83% | 42.52 | 0.98% |
BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 23.41 | 1.93B | -0.38% | n/a | 19.35% |
Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 39.26 | 1.87B | -5.37% | n/a | 138.24% |
Intellia Therapeutics Inc | NTLA | Biotechnology | 17.99 | 1.83B | -3.02% | n/a | 10.95% |
VIRIDIAN THERAPEUTICS ORS INC | VRDN | Biotechnology | 23.92 | 1.83B | -1.36% | n/a | 3.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -31.50 | 0.76 | Cheaper |
Ent. to Revenue | 1.18 | 3,674.48 | Cheaper |
PE Ratio | 55.25 | 38.01 | Expensive |
Price to Book | 0.60 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 36.53 | 74.67 | Lower Risk |
Debt to Equity | - | -1.82 | - |
Debt to Assets | - | 0.26 | - |
Market Cap | 1.92B | 3.73B | Emerging |